论文部分内容阅读
重组白细胞介素-2(rIL-2)是治疗癌症有前途的新药。Rozenbeg等人首次在成人中应用了重组rIL-2的免疫方法,提示有诱导晚期癌肿的消退作用,但有严重的肾毒性,Cochat首次用rIL-2免疫疗法治疗儿童晚期的成神经细胞瘤,以弄清此疗法对儿童代谢和肾脏的影响。病人和方法:Cochat研究了15例患儿(13例)为脱期成神经细胞瘤,1例肾肉瘤、1例淋巴瘤接受了rIL-2的21个周期的治疗,其中6例在第一周期结束后的四周进行了第二周期的rIL-2的治疗,给予
Recombinant interleukin-2 (rIL-2) is a promising new drug for the treatment of cancer. Rozenbeg et al. used recombinant rIL-2 immunotherapy for the first time in adults, suggesting that the induction of advanced cancer has a regression effect but severe nephrotoxicity. Cochit first used rIL-2 immunotherapy to treat advanced neuroblastoma in children. To understand the effects of this therapy on children’s metabolism and kidneys. PATIENTS AND METHODS: Cochat studied 15 patients (13 cases) with peri- degenerating neuroblastoma, 1 case of renal sarcoma, and 1 case of lymphoma treated with 21 cycles of rIL-2, of which 6 cases were first Four weeks after the end of the cycle, a second cycle of rIL-2 treatment was given.